Breast Cancer
Cancer Type
Tumor Tissue (FFPE)
Specimen Requirements
6 Working Days
Turnaround Time ¹
ACTDrug® Breast is an NGS‑based test that detects 16 clinically actionable genes in breast tumor tissue. These genes align with FDA‑approved and NCCN-guideline-recommended targeted therapies, supporting timely and informed treatment decisions.
Actionable Insights for Timely Treatment Options
16
Cancer Genes
11
Fusion Genes
6
Days Turnaround Time
Hallmarks of ACTDrug® Breast
16 genes
Assesses clinically relevant gene alterations for breast cancer, aligned with FDA-approved and NCCN guideline-recommended targeted therapies, supporting informedfirst-line treatment decisions
Whole Coding-Region Design
Comprehensive variant detection and identification of clinically actionable alterations.
Resistance Mutation Insight
Provides genomic insights into variants associated with treatment resistance.
RNA-based NGS Fusion Detection
Enables assessment of known and novel gene fusion events, supporting the identification of patients who may benefit from targeted therapy.
6 Working Days
Rapid turnaround time.
Summary
Actionable Insights of Biomarkers for Your Cancer Patient
Provides genomic profiling for clinically actionable genes. Specifically for breast cancer.
Timely Treatment Options Through CancerGenomic Profiling
ACTDrug® Breast is a next-generation sequencing (NGS)-based assay that provides 16 actionable genes tailored for breast cancer. Sequencing is performed from cancer specimens in our CAP-accredited laboratory. This assay is designed for breast cancer patients, providing tailored genomic profiling and targeted drug recommendations.
Explore Various Genetic Alterations for More Therapeutic Implications
ACTDrug® Breast performs various genetic variation analyses. In addition to single-nucleotide variation (SNV) and small insertions/deletions (InDels), the assay detects copy number variations (CNVs), large genomic rearrangements in BRCA1 and BRCA2, gene fusions, and microsatellite instability (MSI), providing clinically relevant alterations.
For Breast Cancer Management
Selects the most suitable treatment for newly diagnosed advanced and/ or metastatic patients based on actionable genetic mutations.
Easy-to-Interpret Medical Report
Actionable summary of the detected variant and associated therapies. Variant reporting and classification are based on levels of evidence, prioritizing treatment-related evidence supported by international publications and guidelines.
Technical Specifications
Next Generation Sequencing (NGS)
16 actionable genes
Specimen Requirements2
FFPE Tumor Tissue
5-20 unstained sections (5 μm/slide, surface area ≥ 125 mm2)
1 H&E-stained slide (5 μm)
Sequencing Mean Depth
≥ 600 x
Sensitivity3
SNV and Indels: 100%, CNAs: 95%, LGR(BRCA1/2): 100%, Fusion 100%, MSI: 100%
Specificity 3
SNV and Indels: 100%, CNAs: 100%, LGR(BRCA1/2): 94%, Fusion 100%, MSI: 94%
Documentation
Disclaimers / Footnotes
- Turnaround time starts from the date of receipt of qualified samples at our CAP-accredited laboratory.
- Please refer to our specimen instructions.
- Analytical performance was established under defined validation conditions
